{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:19Z","timestamp":1791849499124,"version":"4.3.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chronic Kidney Disease (CKD) is a global chronic disease with increasing prevalence in recent years, particularly CKD accompanied by Secondary Hyperparathyroidism (SHPT) leads to reduced quality of life, increased mortality, a considerable economic burden for patients and society. The aim of this study was to investigate the cost-effectiveness analysis of paricalcitol vs. calcitriol + cinacalcet for CKD patients with SHPT in China in 2020.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A Markov model was conducted employing data derived from published literature, clinical trials, official sources, and tertiary public hospital data in China, based on a 10-year horizon from the perspective of the healthcare system. Calcitriol + Cinacalcet was used as the reference group. CKD stage 5 (CKD-5) dialysis patients suffering from SHPT were included in the study. Effectiveness was measured in quality-adjusted life years (QALYs). The discount rate (5%) was applied to costs and effectiveness. Sensitivity analysis was performed to confirm the robustness of the findings.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The base case analysis demonstrated that Patients treated with paricalcitol could gain an increase in utility (0.183 QALYs) and require fewer expenditures (6925.612 yuan). One-way sensitivity analysis was performed to showed that impact factors were the price of cinacalcet, the hospitalization costs of patients with paricalcitol and calcitriol, the costs and utilities of hemodialysis and the costs of calcitriol, the costs of paricalcitol regardless of period. Probabilistic simulation analysis displayed when willingness-to-pay was \u00a5217113, the probability that Paricalcitol was dominant is 96.20%.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The results showed that paricalcitol administrated to treat patients diagnosed with Secondary hyperparathyroidism in Chronic Kidney Disease, compared to calcitriol and cinacalcet, might be dominant in China.<\/jats:p>","DOI":"10.3389\/fpubh.2021.712027","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T07:01:03Z","timestamp":1626850863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhuolin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS ONE"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ekir.2018.05.011","article-title":"Prevalence and risk factors for CKD: a comparison between the adult populations in China and the United States","volume":"3","author":"Wang","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5414\/CNP86S104","article-title":"Current burden of end-stage kidney disease and its future trend in China","volume":"86","author":"Zhang","year":"2016","journal-title":"Clin Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12882-016-0269-8","article-title":"Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025","volume":"17","author":"Sun","year":"2016","journal-title":"BMC Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-981-13-8871-2_1","article-title":"Prevalence and disease burden of chronic kidney disease","volume":"1165","author":"Lv","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semnephrol.2016.05.008","article-title":"The economic burden of chronic kidney disease and end-stage renal disease","volume":"36","author":"Wang","year":"2016","journal-title":"Semin Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1744-9987.12760","article-title":"Comparison of paricalcitol and calcitriol in dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled studies","volume":"23","author":"Zhang","year":"2019","journal-title":"Ther Apher Dial"},{"key":"B11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12882-017-0665-8","article-title":"Hemodialysis patients' preferences for the management of secondary hyperparathyroidism","volume":"18","author":"Hauber","year":"2017","journal-title":"BMC Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.diabres.2017.02.032","article-title":"Experts consensus on calcimimetics in patients with chronic kidney disease","volume":"34","year":"2018","journal-title":"Chin J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2165\/00044011-200626110-00002","article-title":"Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis","volume":"26","author":"Rosery","year":"2006","journal-title":"Clin Drug Investig"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/14728214.2015.1018177","article-title":"Emerging drugs for secondary hyperparathyroidism","volume":"20","author":"Cozzolino","year":"2015","journal-title":"Exp Opin Emerg Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/1744-9987.12772","article-title":"Secondary hyperparathyroidism: pathogenesis and latest treatment","volume":"23","author":"Mizobuchi","year":"2019","journal-title":"Ther Apher Dial"},{"key":"B16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3803\/EnM.2019.34.4.367","article-title":"Impact of subtotal parathyroidectomy on clinical parameters and quality of life in hemodialysis patients with secondary hyperparathyroidism","volume":"34","author":"El-Kholey","year":"2019","journal-title":"Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US renal data system 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.kisu.2020.09.001","article-title":"China kidney disease network (CK-NET) 2016 annual data report","volume":"10","author":"Zhang","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jval.2015.08.007","article-title":"Economic evaluation of cinacalcet in the United States: the EVOLVE trial","volume":"18","author":"Belozeroff","year":"2015","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/13696998.2019.1693385","article-title":"The cost- effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3\u20134 CKD","volume":"23","author":"Kalantar-Zadeh","year":"2020","journal-title":"J Med Econ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/nu9040328","article-title":"Vitamin D in chronic kidney disease and dialysis patients","volume":"9","author":"Jean","year":"2017","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nep.12029","article-title":"Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism","volume":"18","author":"Ong","year":"2013","journal-title":"Nephrology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/1744-9987.12242","article-title":"Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"19","author":"Akizawa","year":"2015","journal-title":"Ther Apher Dial"},{"key":"B27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2369-14-199","article-title":"Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies","volume":"14","author":"Zheng","year":"2013","journal-title":"BMC Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","article-title":"Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study","volume":"34","author":"Tonbul","year":"2012","journal-title":"Ren Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40261-014-0264-4","article-title":"Health economic evaluation of paricalcitol(\u00ae) versus cinacalcet + calcitriol (oral) in Italy","volume":"35","author":"Nuijten","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2165\/11536310-000000000-00000","article-title":"Cost Effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model","volume":"30","author":"Nuijten","year":"2010","journal-title":"Clin Drug Investig"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1185\/03007990902844097","article-title":"Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective","volume":"25","author":"Nuijten","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"B34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5935\/0101-2800.20160048","article-title":"Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective","volume":"38","author":"Menezes","year":"2016","journal-title":"J Bras Nefrol."},{"key":"B35","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Liu","year":"2020"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3760\/cma.j.issn.0254","article-title":"Analysis of causes of death in elderly patients undergoing hemodialysis and peritoneal dialysis","volume":"39","author":"Chen","year":"2020","journal-title":"Chin J Geriatr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5414\/CNP63454","article-title":"Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"63","author":"Staniforth","year":"2005","journal-title":"Clin Nephrol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3111\/13696998.2013.823092","article-title":"Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients","volume":"16","author":"Sharma","year":"2013","journal-title":"J Med Econ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.13688\/j.cnki.chr.2018.17794","article-title":"Analysis on treatment burden of end-stage renal disease patients and related policy suggestions","volume":"21","author":"Wang","year":"2018","journal-title":"Chinese Health Resources"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s11136-015-0964-0","article-title":"Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore","volume":"24","author":"Yang","year":"2015","journal-title":"Qual Life Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/ndt\/gfy215","article-title":"Returning to hemodialysis after kidney allograft failure: a survival study with propensity score matching","volume":"34","author":"Javier","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B42","article-title":"Statistical Communique of the People's Republic of China on the 2020 National Economic and Social Development","year":"2021"},{"key":"B43","unstructured":"Drug Prices of Centralized Drug Procurement Fell by an Average of 52% in Pilot Cities2019"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/tri.13323","article-title":"Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial","volume":"31","author":"Oblak","year":"2018","journal-title":"Transpl Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00467-017-3579-6","article-title":"Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease","volume":"32","author":"Webb","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","article-title":"Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis","volume":"49","author":"Greenbaum","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1111\/bph.15048","article-title":"Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure","volume":"177","author":"Tamayo","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7907605","DOI":"10.1155\/2020\/7907605","article-title":"The therapeutic effect of active vitamin D supplementation in preventing the progression of diabetic nephropathy in a diabetic mouse model","volume":"2020","author":"Nakhoul","year":"2020","journal-title":"J Diabetes Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000492918","article-title":"The importance of adherence in the treatment of secondary hyperparathyroidism","volume":"47","author":"Alfieri","year":"2019","journal-title":"Blood Purif"},{"key":"B50","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/sdi.12833","article-title":"Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient","volume":"32","author":"Kakani","year":"2019","journal-title":"Semin Dial"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/ndt\/gfx044","article-title":"Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review","volume":"32","author":"Plas","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e0187025","DOI":"10.1371\/journal.pone.0187025","article-title":"Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - a systematic review and meta-analysis","volume":"12","author":"Apetrii","year":"2017","journal-title":"PLoS ONE"},{"key":"B53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.ajkd.2011.12.034","article-title":"Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan","volume":"60","author":"Komaba","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1053\/j.ajkd.2007.03.009","article-title":"Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis","volume":"49","author":"Narayan","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/0886022X.2018.1562356","article-title":"The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism","volume":"41","author":"Susantitaphong","year":"2019","journal-title":"Ren Fail"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1093\/ndt\/gfq641","article-title":"Effectiveness of cinacalcet in patients with recurrent\/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study","volume":"26","author":"Zitt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11255-020-02394-1","article-title":"Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China","volume":"52","author":"Wu","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/nep.13449","article-title":"Perspectives in renal replacement therapy: haemodialysis","volume":"23","author":"Liew","year":"2018","journal-title":"Nephrology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.12659\/MSM.909404","article-title":"Association of dose and frequency on the survival of patients on maintenance of hemodialysis in China: a Kaplan-Meier and cox-proportional hazard model analysis","volume":"24","author":"Sun","year":"2018","journal-title":"Med Sci Monit"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.712027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T07:01:11Z","timestamp":1626850871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.712027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":60,"alternative-id":["10.3389\/fpubh.2021.712027"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.712027","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"article-number":"712027"}}